2.93
-0.02 (-0.85%)
| Penutupan Terdahulu | 2.96 |
| Buka | 2.99 |
| Jumlah Dagangan | 462 |
| Purata Dagangan (3B) | 219 |
| Modal Pasaran | 1,857,464,832 |
| Harga / Jualan (P/S) | 8.63 |
| Harga / Buku (P/B) | 1.08 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Aug 2025 - 1 Sep 2025 |
| Margin Keuntungan | -203.39% |
| Margin Operasi (TTM) | -127.07% |
| EPS Cair (TTM) | -0.010 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -6.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.84% |
| Nisbah Semasa (MRQ) | 3.95 |
| Aliran Tunai Operasi (OCF TTM) | -2.92 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.19 M |
| Pulangan Atas Aset (ROA TTM) | -7.35% |
| Pulangan Atas Ekuiti (ROE TTM) | -38.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (GB) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | RELIEF THERAPEUTICS HOLDING SA | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -2.0 |
| Purata | 0.25 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | 1.08 |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.30 |
| IOVANCE BIOTHERAPEUTICS INC IOV | 304 M | - | - | - |
| PURETECH HEALTH PLC ORD 1P | 292 M | - | 9.31 | 1.07 |
| FARON PHARMACEUTICALS OY ORD NP | 231 M | - | - | 165.73 |
|
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.00% |
| % Dimiliki oleh Institusi | 23.11% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |